nodes	percent_of_prediction	percent_of_DWPC	metapath
Vilazodone—CYP2D6—Temsirolimus—kidney cancer	0.121	0.169	CbGbCtD
Vilazodone—CYP3A4—Everolimus—kidney cancer	0.114	0.159	CbGbCtD
Vilazodone—CYP3A4—Temsirolimus—kidney cancer	0.0772	0.108	CbGbCtD
Vilazodone—CYP2D6—Pazopanib—kidney cancer	0.0638	0.0889	CbGbCtD
Vilazodone—CYP2D6—Erlotinib—kidney cancer	0.0455	0.0635	CbGbCtD
Vilazodone—CYP3A4—Pazopanib—kidney cancer	0.0405	0.0565	CbGbCtD
Vilazodone—CYP2D6—Sorafenib—kidney cancer	0.037	0.0516	CbGbCtD
Vilazodone—CYP2D6—Vinblastine—kidney cancer	0.0365	0.051	CbGbCtD
Vilazodone—CYP3A4—Erlotinib—kidney cancer	0.0289	0.0404	CbGbCtD
Vilazodone—CYP3A4—Paclitaxel—kidney cancer	0.0265	0.0369	CbGbCtD
Vilazodone—CYP3A4—Sorafenib—kidney cancer	0.0235	0.0328	CbGbCtD
Vilazodone—CYP3A4—Vinblastine—kidney cancer	0.0232	0.0324	CbGbCtD
Vilazodone—CYP3A4—Vincristine—kidney cancer	0.0228	0.0319	CbGbCtD
Vilazodone—CYP2D6—Doxorubicin—kidney cancer	0.0224	0.0313	CbGbCtD
Vilazodone—CYP3A4—Sunitinib—kidney cancer	0.0191	0.0266	CbGbCtD
Vilazodone—CYP3A4—Doxorubicin—kidney cancer	0.0143	0.0199	CbGbCtD
Vilazodone—Convulsion—Everolimus—kidney cancer	0.000931	0.0034	CcSEcCtD
Vilazodone—Gastroenteritis—Capecitabine—kidney cancer	0.000927	0.00338	CcSEcCtD
Vilazodone—Arthralgia—Everolimus—kidney cancer	0.000915	0.00334	CcSEcCtD
Vilazodone—Dysgeusia—Sorafenib—kidney cancer	0.000913	0.00333	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Everolimus—kidney cancer	0.000908	0.00331	CcSEcCtD
Vilazodone—Breast disorder—Paclitaxel—kidney cancer	0.000905	0.0033	CcSEcCtD
Vilazodone—Mental disorder—Sunitinib—kidney cancer	0.000903	0.00329	CcSEcCtD
Vilazodone—Malnutrition—Sunitinib—kidney cancer	0.000897	0.00327	CcSEcCtD
Vilazodone—Dry mouth—Everolimus—kidney cancer	0.000895	0.00326	CcSEcCtD
Vilazodone—Libido decreased—Capecitabine—kidney cancer	0.000886	0.00323	CcSEcCtD
Vilazodone—Flatulence—Sunitinib—kidney cancer	0.000884	0.00323	CcSEcCtD
Vilazodone—Arthralgia—Erlotinib—kidney cancer	0.000883	0.00322	CcSEcCtD
Vilazodone—Dysgeusia—Sunitinib—kidney cancer	0.000879	0.00321	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—kidney cancer	0.000876	0.0032	CcSEcCtD
Vilazodone—Increased appetite—Capecitabine—kidney cancer	0.000874	0.00319	CcSEcCtD
Vilazodone—Hallucination—Vincristine—kidney cancer	0.000868	0.00316	CcSEcCtD
Vilazodone—Nervous system disorder—Everolimus—kidney cancer	0.00086	0.00314	CcSEcCtD
Vilazodone—Connective tissue disorder—Vincristine—kidney cancer	0.000857	0.00313	CcSEcCtD
Vilazodone—Skin disorder—Everolimus—kidney cancer	0.000852	0.00311	CcSEcCtD
Vilazodone—Hyperhidrosis—Everolimus—kidney cancer	0.000848	0.00309	CcSEcCtD
Vilazodone—Asthenia—Temsirolimus—kidney cancer	0.000846	0.00308	CcSEcCtD
Vilazodone—Nervous system disorder—Erlotinib—kidney cancer	0.00083	0.00303	CcSEcCtD
Vilazodone—Hyponatraemia—Capecitabine—kidney cancer	0.000825	0.00301	CcSEcCtD
Vilazodone—Skin disorder—Erlotinib—kidney cancer	0.000822	0.003	CcSEcCtD
Vilazodone—Disturbance in sexual arousal—Capecitabine—kidney cancer	0.000815	0.00297	CcSEcCtD
Vilazodone—Connective tissue disorder—Gemcitabine—kidney cancer	0.000813	0.00296	CcSEcCtD
Vilazodone—Cardiac disorder—Vincristine—kidney cancer	0.000809	0.00295	CcSEcCtD
Vilazodone—Migraine—Capecitabine—kidney cancer	0.000809	0.00295	CcSEcCtD
Vilazodone—Ventricular extrasystoles—Doxorubicin—kidney cancer	0.000808	0.00295	CcSEcCtD
Vilazodone—Diarrhoea—Temsirolimus—kidney cancer	0.000806	0.00294	CcSEcCtD
Vilazodone—Pollakiuria—Paclitaxel—kidney cancer	0.000799	0.00292	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Everolimus—kidney cancer	0.000799	0.00291	CcSEcCtD
Vilazodone—Asthenia—Pazopanib—kidney cancer	0.000797	0.00291	CcSEcCtD
Vilazodone—Arthralgia—Sorafenib—kidney cancer	0.000794	0.0029	CcSEcCtD
Vilazodone—Insomnia—Everolimus—kidney cancer	0.000793	0.00289	CcSEcCtD
Vilazodone—Paraesthesia—Vinblastine—kidney cancer	0.00079	0.00288	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	0.000788	0.00288	CcSEcCtD
Vilazodone—Paraesthesia—Everolimus—kidney cancer	0.000787	0.00287	CcSEcCtD
Vilazodone—Irritability—Capecitabine—kidney cancer	0.000784	0.00286	CcSEcCtD
Vilazodone—Somnolence—Everolimus—kidney cancer	0.000779	0.00284	CcSEcCtD
Vilazodone—Dizziness—Temsirolimus—kidney cancer	0.000779	0.00284	CcSEcCtD
Vilazodone—Convulsion—Sunitinib—kidney cancer	0.000777	0.00284	CcSEcCtD
Vilazodone—Dry mouth—Sorafenib—kidney cancer	0.000776	0.00283	CcSEcCtD
Vilazodone—Dyspepsia—Everolimus—kidney cancer	0.000772	0.00282	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Erlotinib—kidney cancer	0.000771	0.00281	CcSEcCtD
Vilazodone—Cardiac disorder—Gemcitabine—kidney cancer	0.000768	0.0028	CcSEcCtD
Vilazodone—Insomnia—Erlotinib—kidney cancer	0.000765	0.00279	CcSEcCtD
Vilazodone—Decreased appetite—Vinblastine—kidney cancer	0.000765	0.00279	CcSEcCtD
Vilazodone—Arthralgia—Sunitinib—kidney cancer	0.000764	0.00279	CcSEcCtD
Vilazodone—Mental disorder—Vincristine—kidney cancer	0.000764	0.00279	CcSEcCtD
Vilazodone—Decreased appetite—Everolimus—kidney cancer	0.000762	0.00278	CcSEcCtD
Vilazodone—Diarrhoea—Pazopanib—kidney cancer	0.00076	0.00277	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.000759	0.00277	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Everolimus—kidney cancer	0.000757	0.00276	CcSEcCtD
Vilazodone—Fatigue—Everolimus—kidney cancer	0.000756	0.00276	CcSEcCtD
Vilazodone—Vomiting—Temsirolimus—kidney cancer	0.000749	0.00273	CcSEcCtD
Vilazodone—Dry mouth—Sunitinib—kidney cancer	0.000747	0.00273	CcSEcCtD
Vilazodone—Nervous system disorder—Sorafenib—kidney cancer	0.000746	0.00272	CcSEcCtD
Vilazodone—Dyspepsia—Erlotinib—kidney cancer	0.000745	0.00272	CcSEcCtD
Vilazodone—Breast disorder—Capecitabine—kidney cancer	0.000742	0.00271	CcSEcCtD
Vilazodone—Skin disorder—Sorafenib—kidney cancer	0.000739	0.0027	CcSEcCtD
Vilazodone—Decreased appetite—Erlotinib—kidney cancer	0.000735	0.00268	CcSEcCtD
Vilazodone—Dizziness—Pazopanib—kidney cancer	0.000734	0.00268	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Erlotinib—kidney cancer	0.00073	0.00266	CcSEcCtD
Vilazodone—Fatigue—Erlotinib—kidney cancer	0.000729	0.00266	CcSEcCtD
Vilazodone—Feeling abnormal—Vinblastine—kidney cancer	0.000725	0.00265	CcSEcCtD
Vilazodone—Feeling abnormal—Everolimus—kidney cancer	0.000723	0.00264	CcSEcCtD
Vilazodone—Abnormal dreams—Doxorubicin—kidney cancer	0.000721	0.00263	CcSEcCtD
Vilazodone—Nervous system disorder—Sunitinib—kidney cancer	0.000718	0.00262	CcSEcCtD
Vilazodone—Skin disorder—Sunitinib—kidney cancer	0.000711	0.00259	CcSEcCtD
Vilazodone—Vomiting—Pazopanib—kidney cancer	0.000706	0.00258	CcSEcCtD
Vilazodone—Nausea—Temsirolimus—kidney cancer	0.0007	0.00255	CcSEcCtD
Vilazodone—Agitation—Vincristine—kidney cancer	0.000697	0.00254	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Sorafenib—kidney cancer	0.000693	0.00253	CcSEcCtD
Vilazodone—Connective tissue disorder—Paclitaxel—kidney cancer	0.000681	0.00248	CcSEcCtD
Vilazodone—Dry eye—Doxorubicin—kidney cancer	0.000674	0.00246	CcSEcCtD
Vilazodone—Dyspepsia—Sorafenib—kidney cancer	0.00067	0.00244	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.000667	0.00243	CcSEcCtD
Vilazodone—Insomnia—Sunitinib—kidney cancer	0.000662	0.00242	CcSEcCtD
Vilazodone—Decreased appetite—Sorafenib—kidney cancer	0.000662	0.00241	CcSEcCtD
Vilazodone—Nausea—Pazopanib—kidney cancer	0.00066	0.00241	CcSEcCtD
Vilazodone—Paraesthesia—Sunitinib—kidney cancer	0.000658	0.0024	CcSEcCtD
Vilazodone—Convulsion—Vincristine—kidney cancer	0.000658	0.0024	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000657	0.0024	CcSEcCtD
Vilazodone—Fatigue—Sorafenib—kidney cancer	0.000656	0.00239	CcSEcCtD
Vilazodone—Eye disorder—Paclitaxel—kidney cancer	0.000647	0.00236	CcSEcCtD
Vilazodone—Dyspepsia—Sunitinib—kidney cancer	0.000645	0.00235	CcSEcCtD
Vilazodone—Cardiac disorder—Paclitaxel—kidney cancer	0.000643	0.00234	CcSEcCtD
Vilazodone—Decreased appetite—Sunitinib—kidney cancer	0.000637	0.00232	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000632	0.00231	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.000632	0.0023	CcSEcCtD
Vilazodone—Asthenia—Vinblastine—kidney cancer	0.000632	0.0023	CcSEcCtD
Vilazodone—Fatigue—Sunitinib—kidney cancer	0.000631	0.0023	CcSEcCtD
Vilazodone—Asthenia—Everolimus—kidney cancer	0.000629	0.00229	CcSEcCtD
Vilazodone—Arthralgia—Gemcitabine—kidney cancer	0.000613	0.00224	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000609	0.00222	CcSEcCtD
Vilazodone—Nervous system disorder—Vincristine—kidney cancer	0.000607	0.00222	CcSEcCtD
Vilazodone—Asthenia—Erlotinib—kidney cancer	0.000607	0.00221	CcSEcCtD
Vilazodone—Mental disorder—Paclitaxel—kidney cancer	0.000607	0.00221	CcSEcCtD
Vilazodone—Malnutrition—Paclitaxel—kidney cancer	0.000603	0.0022	CcSEcCtD
Vilazodone—Decreased appetite—Dactinomycin—kidney cancer	0.000603	0.0022	CcSEcCtD
Vilazodone—Diarrhoea—Vinblastine—kidney cancer	0.000602	0.0022	CcSEcCtD
Vilazodone—Diarrhoea—Everolimus—kidney cancer	0.0006	0.00219	CcSEcCtD
Vilazodone—Hyperhidrosis—Vincristine—kidney cancer	0.000599	0.00218	CcSEcCtD
Vilazodone—Fatigue—Dactinomycin—kidney cancer	0.000598	0.00218	CcSEcCtD
Vilazodone—Flatulence—Paclitaxel—kidney cancer	0.000594	0.00217	CcSEcCtD
Vilazodone—Dysgeusia—Paclitaxel—kidney cancer	0.00059	0.00215	CcSEcCtD
Vilazodone—Nervousness—Paclitaxel—kidney cancer	0.000586	0.00214	CcSEcCtD
Vilazodone—Dizziness—Vinblastine—kidney cancer	0.000582	0.00212	CcSEcCtD
Vilazodone—Dizziness—Everolimus—kidney cancer	0.00058	0.00211	CcSEcCtD
Vilazodone—Diarrhoea—Erlotinib—kidney cancer	0.000579	0.00211	CcSEcCtD
Vilazodone—Nervous system disorder—Gemcitabine—kidney cancer	0.000576	0.0021	CcSEcCtD
Vilazodone—Feeling abnormal—Dactinomycin—kidney cancer	0.000571	0.00208	CcSEcCtD
Vilazodone—Skin disorder—Gemcitabine—kidney cancer	0.000571	0.00208	CcSEcCtD
Vilazodone—Vision blurred—Paclitaxel—kidney cancer	0.000568	0.00207	CcSEcCtD
Vilazodone—Hyperhidrosis—Gemcitabine—kidney cancer	0.000568	0.00207	CcSEcCtD
Vilazodone—Tremor—Paclitaxel—kidney cancer	0.000565	0.00206	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Vincristine—kidney cancer	0.000564	0.00206	CcSEcCtD
Vilazodone—Increased appetite—Doxorubicin—kidney cancer	0.000564	0.00206	CcSEcCtD
Vilazodone—Insomnia—Vincristine—kidney cancer	0.00056	0.00204	CcSEcCtD
Vilazodone—Vomiting—Vinblastine—kidney cancer	0.00056	0.00204	CcSEcCtD
Vilazodone—Dizziness—Erlotinib—kidney cancer	0.000559	0.00204	CcSEcCtD
Vilazodone—Connective tissue disorder—Capecitabine—kidney cancer	0.000558	0.00204	CcSEcCtD
Vilazodone—Vomiting—Everolimus—kidney cancer	0.000557	0.00203	CcSEcCtD
Vilazodone—Paraesthesia—Vincristine—kidney cancer	0.000556	0.00203	CcSEcCtD
Vilazodone—Agitation—Paclitaxel—kidney cancer	0.000554	0.00202	CcSEcCtD
Vilazodone—Asthenia—Sorafenib—kidney cancer	0.000546	0.00199	CcSEcCtD
Vilazodone—Decreased appetite—Vincristine—kidney cancer	0.000538	0.00196	CcSEcCtD
Vilazodone—Vomiting—Erlotinib—kidney cancer	0.000538	0.00196	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000535	0.00195	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Vincristine—kidney cancer	0.000535	0.00195	CcSEcCtD
Vilazodone—Fatigue—Vincristine—kidney cancer	0.000534	0.00195	CcSEcCtD
Vilazodone—Palpitations—Paclitaxel—kidney cancer	0.000533	0.00194	CcSEcCtD
Vilazodone—Hyponatraemia—Doxorubicin—kidney cancer	0.000532	0.00194	CcSEcCtD
Vilazodone—Insomnia—Gemcitabine—kidney cancer	0.000531	0.00194	CcSEcCtD
Vilazodone—Eye disorder—Capecitabine—kidney cancer	0.000531	0.00194	CcSEcCtD
Vilazodone—Paraesthesia—Gemcitabine—kidney cancer	0.000528	0.00192	CcSEcCtD
Vilazodone—Cardiac disorder—Capecitabine—kidney cancer	0.000527	0.00192	CcSEcCtD
Vilazodone—Asthenia—Sunitinib—kidney cancer	0.000525	0.00192	CcSEcCtD
Vilazodone—Nausea—Vinblastine—kidney cancer	0.000523	0.00191	CcSEcCtD
Vilazodone—Somnolence—Gemcitabine—kidney cancer	0.000522	0.00191	CcSEcCtD
Vilazodone—Convulsion—Paclitaxel—kidney cancer	0.000522	0.00191	CcSEcCtD
Vilazodone—Migraine—Doxorubicin—kidney cancer	0.000521	0.0019	CcSEcCtD
Vilazodone—Nausea—Everolimus—kidney cancer	0.000521	0.0019	CcSEcCtD
Vilazodone—Diarrhoea—Sorafenib—kidney cancer	0.000521	0.0019	CcSEcCtD
Vilazodone—Arthralgia—Paclitaxel—kidney cancer	0.000513	0.00187	CcSEcCtD
Vilazodone—Decreased appetite—Gemcitabine—kidney cancer	0.000511	0.00186	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.00051	0.00186	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000507	0.00185	CcSEcCtD
Vilazodone—Fatigue—Gemcitabine—kidney cancer	0.000507	0.00185	CcSEcCtD
Vilazodone—Dizziness—Sorafenib—kidney cancer	0.000503	0.00184	CcSEcCtD
Vilazodone—Nausea—Erlotinib—kidney cancer	0.000503	0.00183	CcSEcCtD
Vilazodone—Dry mouth—Paclitaxel—kidney cancer	0.000502	0.00183	CcSEcCtD
Vilazodone—Diarrhoea—Sunitinib—kidney cancer	0.000501	0.00183	CcSEcCtD
Vilazodone—Mental disorder—Capecitabine—kidney cancer	0.000498	0.00182	CcSEcCtD
Vilazodone—Asthenia—Dactinomycin—kidney cancer	0.000497	0.00181	CcSEcCtD
Vilazodone—Malnutrition—Capecitabine—kidney cancer	0.000495	0.0018	CcSEcCtD
Vilazodone—Flatulence—Capecitabine—kidney cancer	0.000487	0.00178	CcSEcCtD
Vilazodone—Dysgeusia—Capecitabine—kidney cancer	0.000484	0.00177	CcSEcCtD
Vilazodone—Dizziness—Sunitinib—kidney cancer	0.000484	0.00177	CcSEcCtD
Vilazodone—Feeling abnormal—Gemcitabine—kidney cancer	0.000484	0.00177	CcSEcCtD
Vilazodone—Vomiting—Sorafenib—kidney cancer	0.000484	0.00177	CcSEcCtD
Vilazodone—Nervous system disorder—Paclitaxel—kidney cancer	0.000482	0.00176	CcSEcCtD
Vilazodone—Breast disorder—Doxorubicin—kidney cancer	0.000479	0.00175	CcSEcCtD
Vilazodone—Skin disorder—Paclitaxel—kidney cancer	0.000478	0.00174	CcSEcCtD
Vilazodone—Hyperhidrosis—Paclitaxel—kidney cancer	0.000476	0.00173	CcSEcCtD
Vilazodone—Diarrhoea—Dactinomycin—kidney cancer	0.000474	0.00173	CcSEcCtD
Vilazodone—Vision blurred—Capecitabine—kidney cancer	0.000466	0.0017	CcSEcCtD
Vilazodone—Vomiting—Sunitinib—kidney cancer	0.000466	0.0017	CcSEcCtD
Vilazodone—Tremor—Capecitabine—kidney cancer	0.000463	0.00169	CcSEcCtD
Vilazodone—Nausea—Sorafenib—kidney cancer	0.000452	0.00165	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000448	0.00163	CcSEcCtD
Vilazodone—Insomnia—Paclitaxel—kidney cancer	0.000445	0.00162	CcSEcCtD
Vilazodone—Asthenia—Vincristine—kidney cancer	0.000444	0.00162	CcSEcCtD
Vilazodone—Paraesthesia—Paclitaxel—kidney cancer	0.000442	0.00161	CcSEcCtD
Vilazodone—Vomiting—Dactinomycin—kidney cancer	0.000441	0.00161	CcSEcCtD
Vilazodone—Somnolence—Paclitaxel—kidney cancer	0.000437	0.0016	CcSEcCtD
Vilazodone—Palpitations—Capecitabine—kidney cancer	0.000437	0.00159	CcSEcCtD
Vilazodone—Nausea—Sunitinib—kidney cancer	0.000435	0.00159	CcSEcCtD
Vilazodone—Dyspepsia—Paclitaxel—kidney cancer	0.000433	0.00158	CcSEcCtD
Vilazodone—Decreased appetite—Paclitaxel—kidney cancer	0.000428	0.00156	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000425	0.00155	CcSEcCtD
Vilazodone—Fatigue—Paclitaxel—kidney cancer	0.000424	0.00155	CcSEcCtD
Vilazodone—Diarrhoea—Vincristine—kidney cancer	0.000424	0.00155	CcSEcCtD
Vilazodone—Pollakiuria—Doxorubicin—kidney cancer	0.000423	0.00154	CcSEcCtD
Vilazodone—Asthenia—Gemcitabine—kidney cancer	0.000422	0.00154	CcSEcCtD
Vilazodone—Arthralgia—Capecitabine—kidney cancer	0.000421	0.00154	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000418	0.00153	CcSEcCtD
Vilazodone—Dry mouth—Capecitabine—kidney cancer	0.000412	0.0015	CcSEcCtD
Vilazodone—Nausea—Dactinomycin—kidney cancer	0.000412	0.0015	CcSEcCtD
Vilazodone—Dizziness—Vincristine—kidney cancer	0.00041	0.00149	CcSEcCtD
Vilazodone—Feeling abnormal—Paclitaxel—kidney cancer	0.000405	0.00148	CcSEcCtD
Vilazodone—Diarrhoea—Gemcitabine—kidney cancer	0.000402	0.00147	CcSEcCtD
Vilazodone—Nervous system disorder—Capecitabine—kidney cancer	0.000396	0.00144	CcSEcCtD
Vilazodone—Vomiting—Vincristine—kidney cancer	0.000394	0.00144	CcSEcCtD
Vilazodone—Skin disorder—Capecitabine—kidney cancer	0.000392	0.00143	CcSEcCtD
Vilazodone—Hyperhidrosis—Capecitabine—kidney cancer	0.00039	0.00142	CcSEcCtD
Vilazodone—Vomiting—Gemcitabine—kidney cancer	0.000374	0.00136	CcSEcCtD
Vilazodone—Nausea—Vincristine—kidney cancer	0.000368	0.00134	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000368	0.00134	CcSEcCtD
Vilazodone—Insomnia—Capecitabine—kidney cancer	0.000365	0.00133	CcSEcCtD
Vilazodone—Paraesthesia—Capecitabine—kidney cancer	0.000363	0.00132	CcSEcCtD
Vilazodone—Connective tissue disorder—Doxorubicin—kidney cancer	0.00036	0.00131	CcSEcCtD
Vilazodone—Dyspepsia—Capecitabine—kidney cancer	0.000355	0.0013	CcSEcCtD
Vilazodone—Asthenia—Paclitaxel—kidney cancer	0.000353	0.00129	CcSEcCtD
Vilazodone—Decreased appetite—Capecitabine—kidney cancer	0.000351	0.00128	CcSEcCtD
Vilazodone—Nausea—Gemcitabine—kidney cancer	0.000349	0.00127	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000349	0.00127	CcSEcCtD
Vilazodone—Fatigue—Capecitabine—kidney cancer	0.000348	0.00127	CcSEcCtD
Vilazodone—Eye disorder—Doxorubicin—kidney cancer	0.000342	0.00125	CcSEcCtD
Vilazodone—Cardiac disorder—Doxorubicin—kidney cancer	0.00034	0.00124	CcSEcCtD
Vilazodone—Diarrhoea—Paclitaxel—kidney cancer	0.000337	0.00123	CcSEcCtD
Vilazodone—Feeling abnormal—Capecitabine—kidney cancer	0.000333	0.00121	CcSEcCtD
Vilazodone—Dizziness—Paclitaxel—kidney cancer	0.000325	0.00119	CcSEcCtD
Vilazodone—Mental disorder—Doxorubicin—kidney cancer	0.000321	0.00117	CcSEcCtD
Vilazodone—Malnutrition—Doxorubicin—kidney cancer	0.000319	0.00116	CcSEcCtD
Vilazodone—Flatulence—Doxorubicin—kidney cancer	0.000314	0.00115	CcSEcCtD
Vilazodone—Vomiting—Paclitaxel—kidney cancer	0.000313	0.00114	CcSEcCtD
Vilazodone—Dysgeusia—Doxorubicin—kidney cancer	0.000312	0.00114	CcSEcCtD
Vilazodone—Nervousness—Doxorubicin—kidney cancer	0.00031	0.00113	CcSEcCtD
Vilazodone—Vision blurred—Doxorubicin—kidney cancer	0.000301	0.0011	CcSEcCtD
Vilazodone—Agitation—Doxorubicin—kidney cancer	0.000293	0.00107	CcSEcCtD
Vilazodone—Nausea—Paclitaxel—kidney cancer	0.000292	0.00107	CcSEcCtD
Vilazodone—Asthenia—Capecitabine—kidney cancer	0.00029	0.00106	CcSEcCtD
Vilazodone—Palpitations—Doxorubicin—kidney cancer	0.000282	0.00103	CcSEcCtD
Vilazodone—Convulsion—Doxorubicin—kidney cancer	0.000276	0.00101	CcSEcCtD
Vilazodone—Diarrhoea—Capecitabine—kidney cancer	0.000276	0.00101	CcSEcCtD
Vilazodone—Arthralgia—Doxorubicin—kidney cancer	0.000271	0.00099	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.00027	0.000983	CcSEcCtD
Vilazodone—Dizziness—Capecitabine—kidney cancer	0.000267	0.000974	CcSEcCtD
Vilazodone—Dry mouth—Doxorubicin—kidney cancer	0.000266	0.000968	CcSEcCtD
Vilazodone—Vomiting—Capecitabine—kidney cancer	0.000257	0.000936	CcSEcCtD
Vilazodone—Nervous system disorder—Doxorubicin—kidney cancer	0.000255	0.000931	CcSEcCtD
Vilazodone—Skin disorder—Doxorubicin—kidney cancer	0.000253	0.000922	CcSEcCtD
Vilazodone—Hyperhidrosis—Doxorubicin—kidney cancer	0.000252	0.000918	CcSEcCtD
Vilazodone—Nausea—Capecitabine—kidney cancer	0.00024	0.000875	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000237	0.000865	CcSEcCtD
Vilazodone—Insomnia—Doxorubicin—kidney cancer	0.000235	0.000859	CcSEcCtD
Vilazodone—Paraesthesia—Doxorubicin—kidney cancer	0.000234	0.000852	CcSEcCtD
Vilazodone—Somnolence—Doxorubicin—kidney cancer	0.000231	0.000844	CcSEcCtD
Vilazodone—Dyspepsia—Doxorubicin—kidney cancer	0.000229	0.000836	CcSEcCtD
Vilazodone—Decreased appetite—Doxorubicin—kidney cancer	0.000226	0.000825	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000225	0.00082	CcSEcCtD
Vilazodone—Fatigue—Doxorubicin—kidney cancer	0.000224	0.000818	CcSEcCtD
Vilazodone—Feeling abnormal—Doxorubicin—kidney cancer	0.000214	0.000782	CcSEcCtD
Vilazodone—Asthenia—Doxorubicin—kidney cancer	0.000187	0.000681	CcSEcCtD
Vilazodone—Diarrhoea—Doxorubicin—kidney cancer	0.000178	0.00065	CcSEcCtD
Vilazodone—Dizziness—Doxorubicin—kidney cancer	0.000172	0.000628	CcSEcCtD
Vilazodone—Vomiting—Doxorubicin—kidney cancer	0.000165	0.000604	CcSEcCtD
Vilazodone—Nausea—Doxorubicin—kidney cancer	0.000155	0.000564	CcSEcCtD
Vilazodone—CYP2D6—Phase 1 - Functionalization of compounds—POMC—kidney cancer	1.88e-05	0.00212	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—ANXA1—kidney cancer	1.88e-05	0.00212	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PGK1—kidney cancer	1.81e-05	0.00204	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—SLC5A3—kidney cancer	1.81e-05	0.00204	CbGpPWpGaD
Vilazodone—SLC6A4—Circadian rythm related genes—JUN—kidney cancer	1.78e-05	0.002	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—LDHB—kidney cancer	1.78e-05	0.002	CbGpPWpGaD
Vilazodone—SLC6A4—Circadian rythm related genes—PTEN—kidney cancer	1.72e-05	0.00194	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—OR4C13—kidney cancer	1.69e-05	0.0019	CbGpPWpGaD
Vilazodone—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	1.65e-05	0.00186	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—ANXA1—kidney cancer	1.65e-05	0.00186	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—LATS1—kidney cancer	1.64e-05	0.00184	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CA9—kidney cancer	1.54e-05	0.00174	CbGpPWpGaD
Vilazodone—CYP2D6—Biological oxidations—GSTP1—kidney cancer	1.54e-05	0.00173	CbGpPWpGaD
Vilazodone—HTR1A—G alpha (i) signalling events—POMC—kidney cancer	1.52e-05	0.00171	CbGpPWpGaD
Vilazodone—CYP2D6—Metapathway biotransformation—GSTP1—kidney cancer	1.52e-05	0.00171	CbGpPWpGaD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—JUN—kidney cancer	1.52e-05	0.00171	CbGpPWpGaD
Vilazodone—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	1.52e-05	0.00171	CbGpPWpGaD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—CTNNB1—kidney cancer	1.51e-05	0.0017	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—AKAP13—kidney cancer	1.49e-05	0.00168	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—GSTT1—kidney cancer	1.45e-05	0.00163	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—LATS1—kidney cancer	1.44e-05	0.00162	CbGpPWpGaD
Vilazodone—CYP2D6—Biological oxidations—GSTM1—kidney cancer	1.42e-05	0.00159	CbGpPWpGaD
Vilazodone—CYP2D6—Metapathway biotransformation—GSTM1—kidney cancer	1.4e-05	0.00157	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—AMER1—kidney cancer	1.39e-05	0.00157	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—PTGS1—kidney cancer	1.36e-05	0.00153	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—AKAP13—kidney cancer	1.35e-05	0.00152	CbGpPWpGaD
Vilazodone—CYP2D6—Biological oxidations—CYP1A1—kidney cancer	1.34e-05	0.00151	CbGpPWpGaD
Vilazodone—DRD2—G alpha (i) signalling events—POMC—kidney cancer	1.34e-05	0.0015	CbGpPWpGaD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—VEGFA—kidney cancer	1.33e-05	0.00149	CbGpPWpGaD
Vilazodone—CYP2D6—Metapathway biotransformation—CYP1A1—kidney cancer	1.32e-05	0.00149	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CRABP1—kidney cancer	1.31e-05	0.00148	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—AKAP13—kidney cancer	1.31e-05	0.00147	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—ITPR2—kidney cancer	1.27e-05	0.00143	CbGpPWpGaD
Vilazodone—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	1.23e-05	0.00139	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—AMER1—kidney cancer	1.22e-05	0.00138	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—ITPR2—kidney cancer	1.22e-05	0.00137	CbGpPWpGaD
Vilazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	1.21e-05	0.00136	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—AKAP13—kidney cancer	1.19e-05	0.00134	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ACY1—kidney cancer	1.18e-05	0.00133	CbGpPWpGaD
Vilazodone—SLC6A4—Circadian rythm related genes—TP53—kidney cancer	1.17e-05	0.00132	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—GPC3—kidney cancer	1.17e-05	0.00131	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CER1—kidney cancer	1.17e-05	0.00131	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—ITPR2—kidney cancer	1.15e-05	0.0013	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—ITPR2—kidney cancer	1.11e-05	0.00125	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—ACHE—kidney cancer	1.11e-05	0.00125	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—GSTT1—kidney cancer	1.11e-05	0.00125	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—JUN—kidney cancer	1.09e-05	0.00122	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—ANXA1—kidney cancer	1.06e-05	0.0012	CbGpPWpGaD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	1.06e-05	0.0012	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—PTEN—kidney cancer	1.05e-05	0.00118	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—SCARB1—kidney cancer	1.05e-05	0.00118	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PTGS1—kidney cancer	1.04e-05	0.00117	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—GPC3—kidney cancer	1.03e-05	0.00115	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CER1—kidney cancer	1.03e-05	0.00115	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PSMD7—kidney cancer	1.02e-05	0.00115	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—ITPR2—kidney cancer	1.01e-05	0.00114	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—GSTP1—kidney cancer	1.01e-05	0.00113	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PDHB—kidney cancer	1e-05	0.00113	CbGpPWpGaD
Vilazodone—CYP2D6—Biological oxidations—POMC—kidney cancer	1e-05	0.00113	CbGpPWpGaD
Vilazodone—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	9.93e-06	0.00112	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SFRP2—kidney cancer	9.93e-06	0.00112	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—BCHE—kidney cancer	9.69e-06	0.00109	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—ANXA1—kidney cancer	9.65e-06	0.00109	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—SLC5A5—kidney cancer	9.57e-06	0.00108	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CCBL1—kidney cancer	9.44e-06	0.00106	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—ANXA1—kidney cancer	9.33e-06	0.00105	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—GSTM1—kidney cancer	9.25e-06	0.00104	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—SLC2A1—kidney cancer	9.24e-06	0.00104	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—POMC—kidney cancer	9.21e-06	0.00104	CbGpPWpGaD
Vilazodone—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	9.13e-06	0.00103	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	8.77e-06	0.000987	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SFRP2—kidney cancer	8.72e-06	0.00098	CbGpPWpGaD
Vilazodone—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	8.65e-06	0.000973	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—ANXA1—kidney cancer	8.47e-06	0.000953	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PPAT—kidney cancer	8.18e-06	0.00092	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GLIPR1—kidney cancer	8.18e-06	0.00092	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—POMC—kidney cancer	8.09e-06	0.00091	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CASP2—kidney cancer	8e-06	0.0009	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—AKAP13—kidney cancer	8e-06	0.0009	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ACY1—kidney cancer	7.72e-06	0.000868	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—GSTP1—kidney cancer	7.71e-06	0.000867	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—APRT—kidney cancer	7.61e-06	0.000856	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—FH—kidney cancer	7.61e-06	0.000856	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—GRB7—kidney cancer	7.32e-06	0.000823	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—ABCB1—kidney cancer	7.3e-06	0.000821	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—TP53—kidney cancer	7.19e-06	0.000809	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GPC3—kidney cancer	7.15e-06	0.000804	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—GSTM1—kidney cancer	7.08e-06	0.000797	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—AKAP13—kidney cancer	7.03e-06	0.00079	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CASP2—kidney cancer	7.03e-06	0.00079	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CA2—kidney cancer	6.96e-06	0.000783	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ITPR2—kidney cancer	6.8e-06	0.000765	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ALAD—kidney cancer	6.78e-06	0.000763	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CYP1A1—kidney cancer	6.72e-06	0.000755	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ST3GAL2—kidney cancer	6.62e-06	0.000744	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PDHB—kidney cancer	6.56e-06	0.000738	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—POMC—kidney cancer	6.54e-06	0.000736	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ALDH1A1—kidney cancer	6.47e-06	0.000727	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—GRB7—kidney cancer	6.43e-06	0.000723	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—SLC5A3—kidney cancer	6.2e-06	0.000697	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PGK1—kidney cancer	6.2e-06	0.000697	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CCBL1—kidney cancer	6.17e-06	0.000694	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CTNNA1—kidney cancer	6.17e-06	0.000694	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—HSPB1—kidney cancer	6.13e-06	0.00069	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—EIF4EBP1—kidney cancer	6.13e-06	0.00069	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—LDHB—kidney cancer	6.08e-06	0.000684	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ITPR2—kidney cancer	5.97e-06	0.000672	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PSMD7—kidney cancer	5.7e-06	0.000641	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TSC1—kidney cancer	5.7e-06	0.000641	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ANXA1—kidney cancer	5.7e-06	0.000641	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—FLT1—kidney cancer	5.52e-06	0.000621	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CTNNA1—kidney cancer	5.42e-06	0.000609	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—HSPB1—kidney cancer	5.38e-06	0.000606	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—EIF4EBP1—kidney cancer	5.38e-06	0.000606	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GLIPR1—kidney cancer	5.35e-06	0.000602	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PPAT—kidney cancer	5.35e-06	0.000602	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CA9—kidney cancer	5.27e-06	0.000593	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—POMC—kidney cancer	5.21e-06	0.000586	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—JUNB—kidney cancer	5.12e-06	0.000576	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PAK1—kidney cancer	5.12e-06	0.000576	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—POMC—kidney cancer	5.01e-06	0.000563	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TSC1—kidney cancer	5.01e-06	0.000563	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ANXA1—kidney cancer	5.01e-06	0.000563	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PSMD7—kidney cancer	5.01e-06	0.000563	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—FH—kidney cancer	4.97e-06	0.000559	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—APRT—kidney cancer	4.97e-06	0.000559	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—FLT1—kidney cancer	4.85e-06	0.000545	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—POMC—kidney cancer	4.73e-06	0.000532	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GPC3—kidney cancer	4.68e-06	0.000526	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—POMC—kidney cancer	4.57e-06	0.000514	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CA2—kidney cancer	4.55e-06	0.000512	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PAK1—kidney cancer	4.49e-06	0.000506	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—JUNB—kidney cancer	4.49e-06	0.000506	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CRABP1—kidney cancer	4.48e-06	0.000504	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ALAD—kidney cancer	4.43e-06	0.000499	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ST3GAL2—kidney cancer	4.33e-06	0.000487	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ALDH1A1—kidney cancer	4.23e-06	0.000476	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IGF2—kidney cancer	4.18e-06	0.000471	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ITPR2—kidney cancer	4.17e-06	0.000469	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CDKN2B—kidney cancer	4.17e-06	0.000469	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—POMC—kidney cancer	4.15e-06	0.000467	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PGK1—kidney cancer	4.05e-06	0.000456	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SLC5A3—kidney cancer	4.05e-06	0.000456	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IGF1R—kidney cancer	4.05e-06	0.000455	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PTGS2—kidney cancer	3.99e-06	0.000449	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—LDHB—kidney cancer	3.98e-06	0.000447	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—RAF1—kidney cancer	3.9e-06	0.000439	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—IL2—kidney cancer	3.85e-06	0.000433	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTT1—kidney cancer	3.8e-06	0.000427	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ACHE—kidney cancer	3.8e-06	0.000427	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IGF2—kidney cancer	3.67e-06	0.000413	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CDKN2B—kidney cancer	3.66e-06	0.000412	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—SCARB1—kidney cancer	3.6e-06	0.000405	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PTGS1—kidney cancer	3.56e-06	0.000401	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IGF1R—kidney cancer	3.55e-06	0.0004	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—IL2—kidney cancer	3.5e-06	0.000393	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PSMD7—kidney cancer	3.49e-06	0.000393	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PTEN—kidney cancer	3.48e-06	0.000392	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CA9—kidney cancer	3.45e-06	0.000388	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—RAF1—kidney cancer	3.42e-06	0.000385	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—IL2—kidney cancer	3.38e-06	0.00038	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—HIF1A—kidney cancer	3.33e-06	0.000375	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TSC2—kidney cancer	3.32e-06	0.000374	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—BCHE—kidney cancer	3.31e-06	0.000372	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—SLC5A5—kidney cancer	3.27e-06	0.000368	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—KDR—kidney cancer	3.19e-06	0.000358	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—SLC2A1—kidney cancer	3.16e-06	0.000355	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—IL2—kidney cancer	3.07e-06	0.000345	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—KIT—kidney cancer	2.93e-06	0.00033	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—APC—kidney cancer	2.93e-06	0.00033	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CRABP1—kidney cancer	2.93e-06	0.00033	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—HIF1A—kidney cancer	2.92e-06	0.000329	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TSC2—kidney cancer	2.92e-06	0.000328	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—MAPK3—kidney cancer	2.81e-06	0.000316	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—KDR—kidney cancer	2.8e-06	0.000315	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—POMC—kidney cancer	2.79e-06	0.000314	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—BRAF—kidney cancer	2.76e-06	0.00031	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ITPR2—kidney cancer	2.72e-06	0.000306	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—MAPK1—kidney cancer	2.67e-06	0.000301	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTP1—kidney cancer	2.63e-06	0.000296	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—APC—kidney cancer	2.58e-06	0.00029	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—KIT—kidney cancer	2.58e-06	0.00029	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—PIK3CA—kidney cancer	2.56e-06	0.000287	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—KRAS—kidney cancer	2.53e-06	0.000284	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ABCB1—kidney cancer	2.49e-06	0.00028	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTT1—kidney cancer	2.48e-06	0.000279	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ACHE—kidney cancer	2.48e-06	0.000279	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—MAPK3—kidney cancer	2.47e-06	0.000278	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PIK3CA—kidney cancer	2.46e-06	0.000276	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—POMC—kidney cancer	2.45e-06	0.000276	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—BRAF—kidney cancer	2.42e-06	0.000272	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTM1—kidney cancer	2.42e-06	0.000272	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SCARB1—kidney cancer	2.35e-06	0.000265	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—MAPK1—kidney cancer	2.35e-06	0.000264	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PTGS1—kidney cancer	2.33e-06	0.000262	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PIK3CA—kidney cancer	2.32e-06	0.000261	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—RAF1—kidney cancer	2.3e-06	0.000259	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP1A1—kidney cancer	2.29e-06	0.000258	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—RELA—kidney cancer	2.29e-06	0.000258	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PSMD7—kidney cancer	2.28e-06	0.000257	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ERBB2—kidney cancer	2.28e-06	0.000256	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MTOR—kidney cancer	2.25e-06	0.000253	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PIK3CA—kidney cancer	2.24e-06	0.000252	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—KRAS—kidney cancer	2.22e-06	0.000249	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—BCHE—kidney cancer	2.16e-06	0.000243	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SLC5A5—kidney cancer	2.14e-06	0.000241	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CDKN1B—kidney cancer	2.11e-06	0.000237	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IL2—kidney cancer	2.07e-06	0.000232	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SLC2A1—kidney cancer	2.06e-06	0.000232	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PIK3CA—kidney cancer	2.04e-06	0.000229	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—RAF1—kidney cancer	2.02e-06	0.000227	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—RELA—kidney cancer	2.01e-06	0.000226	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CCND1—kidney cancer	2.01e-06	0.000226	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—JUN—kidney cancer	2.01e-06	0.000226	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ERBB2—kidney cancer	2e-06	0.000225	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CTNNB1—kidney cancer	1.99e-06	0.000224	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MTOR—kidney cancer	1.97e-06	0.000222	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PTEN—kidney cancer	1.94e-06	0.000219	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CDKN1B—kidney cancer	1.85e-06	0.000208	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IL2—kidney cancer	1.81e-06	0.000204	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CCND1—kidney cancer	1.77e-06	0.000199	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—JUN—kidney cancer	1.76e-06	0.000198	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—VEGFA—kidney cancer	1.75e-06	0.000197	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CTNNB1—kidney cancer	1.75e-06	0.000197	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTP1—kidney cancer	1.72e-06	0.000194	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—POMC—kidney cancer	1.71e-06	0.000192	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PTEN—kidney cancer	1.71e-06	0.000192	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MAPK3—kidney cancer	1.66e-06	0.000187	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ABCB1—kidney cancer	1.63e-06	0.000183	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MYC—kidney cancer	1.61e-06	0.000182	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTM1—kidney cancer	1.58e-06	0.000178	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MAPK1—kidney cancer	1.58e-06	0.000178	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—VEGFA—kidney cancer	1.54e-06	0.000173	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.5e-06	0.000169	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—KRAS—kidney cancer	1.49e-06	0.000168	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MAPK3—kidney cancer	1.46e-06	0.000164	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MYC—kidney cancer	1.42e-06	0.000159	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MAPK1—kidney cancer	1.39e-06	0.000156	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PIK3CA—kidney cancer	1.37e-06	0.000154	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PTGS2—kidney cancer	1.36e-06	0.000154	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TP53—kidney cancer	1.33e-06	0.000149	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—KRAS—kidney cancer	1.31e-06	0.000147	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PIK3CA—kidney cancer	1.2e-06	0.000135	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PTEN—kidney cancer	1.19e-06	0.000134	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TP53—kidney cancer	1.16e-06	0.000131	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—POMC—kidney cancer	1.12e-06	0.000126	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PTGS2—kidney cancer	8.92e-07	0.0001	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PIK3CA—kidney cancer	8.4e-07	9.44e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PTEN—kidney cancer	7.78e-07	8.75e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PIK3CA—kidney cancer	5.49e-07	6.17e-05	CbGpPWpGaD
